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Abstract. Background/Aim: Increased expression and
prognostic significance of major redox regulator nuclear
factor erythroid-2-related factor (Nrf2) is recognized in many
cancers. Our aim was to investigate the role of oxidative
stress markers in melanoma. Materials and Methods: We
characterized the immunohistochemical expression of Nrf2,
kelch-like ECH-associated protein 1 (Keap1), BRAFV600E, 8-
hydroxy-2’-deoxyguanosine (8-OHdG) and nitrotyrosine in 36
nevi, 14 lentigo maligna and 71 malignant melanomas. We
measured Nrf2 expression in melanoma cell lines and
conducted cytotoxicity assays combining BRAF/NRAS
ablation and H2O2 treatment. Results: Nuclear Nrf2
expression in melanoma correlated with deeper Breslow
(p<0.0005), invasive phenotype (Clark III-V) (p=0.011),
nodular growth (p=0.001) and worse melanoma-specific
survival (p=0.008). Absence of 8-OHdG in the endothelium
was a greater significant predictor of poor prognosis
(p=0.024) than ulceration (p=0.17) and had a similar impact
on prognosis as Breslow (p=0.024). A decrease of Nrf2
followed the BRAF/NRAS inhibition, but combination of
inhibitor with H2O2 did not increase cytotoxicity. Conclusion:
Nrf2 and 8-OHdG influence prognosis in melanoma.
Oxidative stress occurs in the presence of oxygen and
reactive oxidative compounds in all aerobic organisms.
Sources of reactive oxygen species are manifold including
mitochondria (respiration by-product superoxide anion),
peroxisomes (hydrogen peroxide), UV-radiation and
inflammation (hydroxyl radical). 8-hydroxydeoxyguanosine
(8-OHdG) is an oxidative damage lesion in DNA caused by
a hydroxyl radical, but it also has antioxidant properties (1,
2). Nitrotyrosine, in turn, reflects nitrosative stress from
peroxynitrite and is a protein adduct that can lead to altered
protein activity or function. As stable footprints of oxidative
stress, both 8-OHdG and nitrotyrosine are widely used as
oxidative stress markers.
Nuclear factor erythroid-2-related factor 2 (Nrf2) is a main
inductor of genes of antioxidant proteins and phase II
detoxifying enzymes. It is sustained inactive by interaction
with kelch-like ECH-associated protein 1 (Keap1) (3). This
interaction is disturbed by many factors including oxidative
stress. Nrf2 is frequently aberrantly activated and accumulated
in the cell nucleus in different cancer types (4). Subsequently
Nrf2 induced redox-state regulating enzyme levels are also
increased. Elevated Nrf2 is noted in many cancer types as a
prognostic and predictive marker. In addition to epigenetic and
mutation-mediated Nrf2 accumulation, mutated oncogenes
HRAS, KRAS, BRAF and c-MYC activate Nrf2 (4, 5).
BRAF mutations occur in about 40-60% of melanomas
and the most common is the BRAFV600E point-mutation,
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whereas NRAS-mutations occur in 15-25% of melanomas.
BRAF and NRAS mutations are mutually exclusive. These
mutations cause cellular growth and promote survival
signaling by constitutive activation of RAF-MEK-ERK
pathway. The outcome of BRAF-mutated melanoma patients
is significantly improved by the development of BRAF-
inhibitors. In the future, combining MAPK pathway
inhibitors might improve survival even further (6, 7). The use
of anti-BRAF antibody VE1 in immunohistochemistry has
been depicted by Long et al. (8) and Thiel et al. (9) in a
prospective setting. BRAF immunohistochemistry is an
accurate, fast, and cost-effective method with sensitivity up
to 100% and a specificity of 97-98%.
We have previously reported that the expression of main
redox-regulating enzymes peroxiredoxins, sulfiredoxin and
DJ-1 are significantly reduced in melanomas compared to
dysplastic and benign nevi in most tumor compartments and
identified sulfiredoxin and peroxiredoxins III and IV as
potential new independent prognostic factors in melanoma
(10). There are no previous studies on melanoma describing
the expression of antioxidant response regulators Nrf2,
Keap1 and oxidative damage lesion 8-OHdG. Thus, we
conducted an immunohistochemical study using specific
antibodies against these targets complemented with
nitrotyrosine and BRAF immunohistochemistry. Acquired
data were correlated with clinicopathological parameters. We
measured Nrf2 levels in four melanoma cell lines before and
after the inhibitor treatment assuming that oncogenic BRAF
and NRAS mutations in melanoma promote Nrf2 expression.
We also conducted a cytotoxicity assay using BRAF and
NRAS inhibitors in induced oxidative environment in vitro,
hypothesizing that oxidative stress can increase the
sensitivity of melanoma cells to the inhibitor via Ras-Raf-
MEK-ERK-pathway-mediated Nrf2 repression. 
Materials and methods 
The study included 121 patient samples collected from paraffin block
archives stored in the Department of Pathology of Oulu University
Hospital between 1999 and 2011. All samples were fixed in neutral
buffered formalin and embedded in paraffin. Cases were randomly
collected based on the diagnosis and the adequacy of the samples. Only
primary melanomas without prior biopsies were included. The series
consisted of 23 benign nevi (8 junctional, 7 compositus, 8 intradermal),
13 dysplastic nevi, 14 lentigo maligna, 15 lentigo malignant
melanomas, 28 nodular melanomas, 20 superficially spreading
melanoma and 8 acral melanoma samples (Table I). Diagnoses were
according to the current WHO classification (11) using S100, HMB45
and/or Melan A in addition to morphology when necessary. 
The clinical data and the data of the pathological diagnosis of the
patients were retrospectively collected from the patient records of
the Oulu University Hospital. Survival data were collected and
complemented with ulceration, Breslow and Clark when reported
(Table I). Median survival was 34.0 months and 24 patients died of
melanoma during follow-up.
Immunohistochemistry. Primary antibodies were mouse monoclonal
anti-8-OHdG (clone N45.1, Japan Institute for the Control of Aging,
Fukuroi, Japan), rabbit polyclonal anti-nitrotyrosine (AB5411,
Millipore, Darmstadt, Germany), rabbit polyclonal anti- Nrf2 (C-
20), goat polyclonal anti- Keap1 (E-20):sc-15246, Santa Cruz
Biotechnology, Inc, TX, USA) and mouse monoclonal anti-BRAF
V600E-specific antibody (VE1; Spring Bioscience, Pleasanton, CA,
USA) designed for formalin-fixed paraffin-embedded tissue sections
for immunohistochemistry. Hematoxylin-eosin staining was
performed to all samples.
Sections of 3-4 μm thickness were de-paraffinised and
rehydrated in graded alcohol. Sections were first heated in a
microwave oven in citrate for 10-15 min and then incubated with
the primary antibody anti-8-OHdG dilution 1:50 for 1 h, anti-
nitrotyrosine dilution 1:750 overnight, anti-Nrf2 dilution 1:200 for
2 h and anti-Keap1 dilution 1:100 1 h. VE1 was used at a dilution
of 1:2,000 for 16 min (diaminobenzidine) and 1:100 for 24 min
(The Fast Red chromogen).
The Invitrogen kit (8-OHdG and Nitrotyrosine), Novolink
Polymer Detection kit (Nrf2) and Biocare goat-on-rodent HRP-
polymer kit (Keap1) were used according to the supplier’s
instructions for the detection of primary antibody. The colour was
developed by diaminobenzidine (Dako, Glostrup, Denmark) and the
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Table I. Patient cohort.
Number of patients 121
Benign naevi 23
Dysplastic naevi 13
Lentigo maligna 14
Malignant primary lesions 71
Lentigo maligna melanoma 15
Nodular melanoma 28
Superficially spreading melanoma 20
Acral melanoma 8
Median age (years) 70 
Gender
Males 46
Females 25
Lesion location
Head and neck 26
Limbs 21
Trunk 19
Data missing 5
Ulceration
Yes 27
No 40
Data missing 4
Breslow
<2 mm 35
2-4 mm 15
> 4 mm 16
Data missing 5
Mean 3.1 mm
Median 1.6 mm
Clark
Radial growth (Clark I–II) 13
Vertical growth (Clark III–V) 50
Data missing 8
sections were counterstained with haematoxylin. The staining
protocol for BRAF V600E with the Fast Red chromogen and
diaminobenzidine is described by Thiel et al. (9).
Immunoreactivities of Nrf2, Keap1, 8-OHdG and nitrotyrosine
were assessed as negative, very weak, weak, moderate or strong
intensity by two investigators, the first author and an experienced
dermatopathologist (K-M.H). The expression of melanocytic
cells, keratinocytes, fibroblasts, endothelial structures, sweat
gland and apocrine gland structures and leukocytes were
separately assessed. BRAF was determined as negative or positive
in melanocytic cells according to Thiel et al. (9). Negative control
samples were used in all processes and were handled as described
previously, but with the primary antibody replaced by serum or
phosphate buffered saline. 
Statistical analysis. In the statistical evaluation of immunoreactivity
intensity groups were pooled into two categories: i) negative to very
weak and ii) weak, moderate to strong staining. Breslow’s thickness
was used as a continuous variable and Clark I-II was pooled to
present a horizontal growth and Clark III-V to present a vertical
growth. Statistical analyses were performed by IBM SPSS Statistics
22 (IBM Corporation, Armonk, NY, USA). The significance of
associations was defined using a 2-sided Chi-square test and a
Mann-Whitney test. The Kaplan-Meier curves with a log-rank test
were applied in the survival analysis and a Cox regression model
with the ulceration status and the Breslow’s thickness was used in a
multivariate analysis. Only malignant melanomas (Lentigo maligna
melanoma, nodular, superficially spreading and acral melanoma,
N=71) were included to the survival analysis and to the analysis
against clinicopathological factors. Only deaths to melanoma were
considered as an endpoint in the survival analysis. p-Values ≤0.05
were considered significant.
Cell lines. The cell lines used in this study were: COLO-800 (ACC
193) and SK-MEL-1 (ACC 303) with BRAF mutation, IPC-298
(ACC 251) and SK-MEL-30 (ACC 151) with NRAS-mutation
ordered from Leibniz-Institut, DSMZ (Braunschweig, Germany).
Cells were cultured in RPMI-1640 with 10% fetal bovine serum and
100 IU/ml penicillin and streptomycin (Pen-Strep solution HyClone
laboratories, Inc. UT, USA). 
Inhibitors. The following inhibitors were used: CI-1040 (PD 184352)
(Alexis Biochemicals, Lausen, Switzerland) and vemurafenib (V-
2800) (LC Laboratories, Woburn, MA, USA). Hydrogen peroxide
was used for the oxidative stress modeling. Drug solutions were
prepared from a 10-mM stock solution before use. Hydrogen
peroxide solution was made from a 30% stock solution (J.T. Baker
Chemicals, Avantor, PA, USA) and used in gradual concentrations
10 μM, 33 μM, 100 μM and 333 μM. CI-1040 is a specific small-
molecule drug inhibiting MEK1/MEK2 by blocking ERK
phosphorylation and is known to inhibit growth of many human
tumor cell lines. Inhibition of MAPK activation by CI-1040 prevents
cell cycle progression and induces a G1 arrest (12). The dose of CI-
1040 was 1 μM in western blot assay and 3.3 μM in cytotoxicity
assay. Vemurafenib is an inhibitor of ERK1/2 in the highly sensitive
BRAFV600E/K -mutated cells (13). Its dose was 1 μM.
Cytotoxicity. The cells were trypsinised (Trypsin 0.25%) and plated
onto 96-well plates with three parallel wells for each treatment and
the experiments were replicated at least three times. Drug treatments
were started the following day, and the plates were developed 72 h
later using either MTS reagent mix ([3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt], Promega; Madison, WI, USA) supplemented with phenazine
methosulfate (Sigma-Aldrich, St. Louis, MO, USA) or with CCK-8
reagent (Dojindo, Rockville, MD, USA) for SK-MEL-1 cell line
according to manufacturer’s guidelines. Absorbances were read on a
plate reader (Anthos Reader 2001, Athos Labtec Instruments;
Salzburg, Austria) at a wavelength of 490 nm or 450nm (CCK-8).
Data was displayed on Microsoft Office Excel 2007. 
Western blot analysis. The cells were trypsinised and then plated
onto 96-well plates and treated with the inhibitors 24 h later for 48
h, after which time they were lysed in RIPA buffer (1% Igepal CA-
630, 20 mM Tris HCl pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM
EDTA, 1 mM sodium orthovanadate, 10 g/ml Aprotinin, 10 g/ml
Leupeptin, and 10 g/ml Pepstatin). The protein concentrations were
measured using the Bio-Rad Protein Assay (Bio-Rad; Hercules, CA,
USA) and the concentrations in individual samples were equalized
before adding 3x Laemmli buffer to a final concentration of 1x.
Equal amounts of protein were run on 7.5% SDS-PAGE gels,
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Table II. Correlation between immunohistochemical expression and histopathological determinants.
Breslow Clark Ulceration
Nrf2 Nucleus p<0.0005 mc p=0.011 mc -
Cytoplasm p=0.015* sg - -
KEAP1 Nucleus - - -
Cytoplasm - p=0.002* lc -
8-OHdG Nucleus - - p=0.037 ec
Cytoplasm p=0.007* mc - -
Nitrotyrosine Nucleus p=0.014 sg - p=0.001 sg, p=0.044 lc
Cytoplasm - p=0.044 ec, p=0.026 sc -
BRAF Nucleus - - -
Cytoplasm p=0.023 mc p=0.002 mc -
kc: Keratinocytes, mc: melanoma cells, sg: sweat glands, sc: sebaceous cells, ec: endothelial cells, lc: lymphocytes. Positive correlation without
marking and inverse correlation marked with an asterisk.
transferred to PVDF membranes, probed with the antibodies and
developed using the ECL chemiluminescence system (Millipore,
Billerica, MA, USA) for detection on radiographic films, which
were scanned to an electronic format. Nrf2 antibody ((C-20): sc-
722) (Santa Cruz Biotechnology) was used as primary antibody and
Anti-rabbit HRP conjugated antibody was used as a secondary
antibody. B-Actin was used to control total protein levels.
Ethical approval. The study was approved by the Finnish National
Supervisory Authority for Welfare and the Health and the Local
Ethics Committee of the Northern Ostrobothnia Hospital District. 
Results
Immunohistochemical expression. Cytoplasmic Nrf2
positivity in pigment cells was associated with malignant
phenotype compared to benign nevi (p=0.008) (Figure 1A-
C). Nuclear Nrf2 staining in melanocytic cells varied and no
significant changes were observed between benign and
malignant samples. Nuclear Nrf2 intensity in melanocytic
cells correlated positively with deeper Breslow (p<0.0005),
associated with Clark III-V (p=0.011) and with nodular type
of malignant melanoma (p=0.001) (Figure 1B, Table I).
None of the superficially-spreading melanoma cases
presented positive Nrf2 in the nuclei of melanoma cells
(Figure 1C). Cytoplasmic intensity of Nrf2 in sweat glands
correlated inversely with Breslow p=0.015.
Keap1 staining was cytoplasmic and mostly varied from
weak to strongly positive in melanocytic cells and
keratinocytes. A significant decrease in cytoplasmic Keap1
expression in keratinocytes was seen (p=0.031) in malignant
samples compared to benign ones. Cytoplasmic Keap1
expression in lymphocytes was more frequent in radial
(Clark I-II) than vertical growth phase (Clark III-IV)
(p=0.002) (Table II).
8-OHdG staining was cytoplasmic and nuclear in all
sample compartments including adjacent adnexal structures.
A significant tendency for malignant samples to be more
negative compared to benign nevi was seen in the cytoplasm
of keratinocytes (p=0.036), fibroblasts (p=7.3486×10–8) and
endothelial structures (p=0.002). Cytoplasmic 8-OHdG
expression in melanocytic cells associated with smaller
Breslow’s thickness (p=0.007) (Figure 1E). Nuclear
endothelial 8-OHdG expression also associated with the
presence of ulceration (p=0.037) (Table II).
Nitrotyrosine staining was both cytoplasmic and nuclear,
being variably present in all structures. Its expression was
more frequently negative in apocrine cells (p=0.024) and
lymphocytes (p=0.000352) in malignant samples compared
to benign nevi. Nuclear nitrotyrosine expression in sweat
(eccrine) glands (p=0.001) or in lymphocytes (p=0.044)
associated with the presence of ulceration in tumor (Table
II). Nuclear nitrotyrosine in sweat glands correlated with
deeper Breslow (p=0.014). In line with this, more intensive
cytoplasmic nitrotyrosine expression in endothelium
(p=0.044) or in apocrine cells (p=0.026) associated with
more vertical than radial growth pattern. 
BRAF staining was cytoplasmic and mostly covered the
whole tumor sample when positive (Figure 1D). It correlated
with Breslow (p=0.023) and associated with vertical growth
(p=0.002) (Table I). BRAF-positivity associated with
cytoplasmic nitrotyrosine expression in both endothelium
(p=0.037) and in apocrine cells (p=0.032) but not with Nrf2,
Keap1 or 8-OHdG expression.
Survival analysis. Patients with weak to strong nuclear Nrf2
expression in pigment cells had a significantly worse survival
(p=0.008) compared to those with a negative to very weak
expression (Figure 2A). Keap1 expression did not predict
outcome, despite of a trend for a better survival in patients
with a weak to strong presence of cytoplasmic Keap1
immunostaining in melanocytic cells (log-rank p=0.089;
Breslow p=0.023) (Figure 1F). A negative to very weak
expression of nuclear 8-OHdG expression in sweat glands
(p=0.017) and endothelial structures (p=0.008) associated
with a worse melanoma-specific survival (Figure 2B and C).
A weak to strong cytoplasmic expression of nitrotyrosine in
apocrine cells associated with a worse survival (p=0.026)
(Figure 2D). Strikingly, none of the patients with a negative
to very weak cytoplasmic nitrotyrosine in apocrine cells died
of melanoma during the follow-up. BRAF-positivity
associated significantly with worse melanoma-specific
survival (p=0.006).
In the Cox regression analysis, a negative or very weak
nuclear 8-OHdG expression in endothelial structures (Figure
2C) was a more significant predictor of a poor prognosis
(risk Ratio (RR) 3.491; 95% confidence interval (CI) 1.183-
10.296; p=0.024) than ulceration (RR=1.935; 95%CI=0.749-
5.000; p=0.17) and had a similar impact to the prognosis as
Breslow (RR 1.130; 95% CI 1.023-1.248; p=0.024) when
these three factors were included to the model. No other new
significant prognostic factors were observed in the
multivariate analysis.
Cell line studies. Based on the clinical data, we hypothesized
that oxidative stress can increase the sensitivity of melanoma
cells to oncogene ablation. We selected B-Raf (COLO-800,
SK-MEL-1) and N-Ras mutant (SK-MEL-30, IPC-298)
melanoma lines for the study since these cell lines show a
dependency on Ras-Raf-MEK-ERK-pathway and are
sensitive to BRAF or MEK inhibition in vitro. All studied
cell lines showed a similar basal level of Nrf2 expression.
When the cell lines were treated with 1 μM vemurafenib or
1 μM CI-1040 for 48 h, all showed a down-regulated
expression of Nrf2 suggesting that its expression was
oncogene-dependent. The down-regulation of Nrf2 was
marked in SK-MEL-1, SK-MEL-30 and IPC-298, while
ANTICANCER RESEARCH 36: 1497-1506 (2016)
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Figure 1. Immunohistochemical staining with diaminobenzidine and hematoxylin. A: Intradermal naevus showing some faint cytoplasmic positivity
in Nrf2 staining. Nuclei remain mostly negative. B: Nodular melanoma with Breslow 6,0 mm. Nrf2-positive nuclear staining is seen in melanoma
cells. C: Superficially spreading melanoma with Breslow 1.2 mm. Increase in cytoplasmic Nrf2 positivity is seen compared to intradermal naevi
(p=0.008). D: The same sample as in picture b. BRAFV600E-positive melanoma, strong cytoplasmic signal. No statistical association between
BRAFV600E and Nrf2. E: Strong cytoplasmic 8-OHdG in melanoma which is associated with smaller Breslow’s thickness (p=0.007). F: Cytoplasmic
Keap1 expression in melanoma cells associates non-significantly to melanoma-specific survival (p=0.089).
COLO-800 presented only a modest down-regulation (Figure
3A). Next we investigated the sensitivity of the tested cell
lines to oncogene ablation, oxidative stress by H2O2
treatment, and combinatory effect of both treatments. We
exposed the cell lines to 1 μM vemurafenib (COLO-800, SK-
MEL-1) or 3.3 μM CI-1040 (SK-MEL-30, IPC-298) and to
varying concentrations of H2O2 (10-333 μM) or their
combinations and analyzed the cytotoxicity by 72-h MTS
assays (Figure 3B-E). The results showed that all the lines
were sensitive to oncogene ablation therapy with a down-
regulation of vital cells by 73-83%. H2O2 treatment resulted
in cytotoxicity in the concentration above 100 μM in all the
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Figure 2. Kaplan–Meier curves showing melanoma-specific survival. A: Negative to very weak expression of Nrf2 in melanoma cell nuclei associates
with worse prognosis. B: and C: Negative to very weak expression of nuclear 8-OHdG in sweat gland cells and endothelial structures adjacent to
melanoma associates with worse prognosis. D: Weak to strong cytoplasmic nitrotyrosine in apocrine cells adjacent to melanoma associates with
worse prognosis.
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tested cell lines without any significant variation.
Combination treatment with vemurafenib or CI-1040 and of
H2O2 resulted in varying results between the cell lines. SK-
MEL-1, SK-MEL-30, and IPC-298 lines showed that H2O2
treatment did not increase the cytotoxicity of oncogene
ablation. Unexpectedly, H2O2 treatment of COLO-800
inhibited the cytotoxicity of vemurafenib to the cell line
when used in low concentrations (10-100 μM) (Figure 3Β).
Discussion
New insights in the up-regulation of Nrf2 protein and its role
in oncogenic functions have been recently presented and
reviewed (14). Nrf2 is best studied in lung carcinomas.
Increased Nrf2 expression has been associated with a worse
overall survival in non-small cell lung cancer and a worse
recurrence-free survival in lung squamous cell carcinoma
patients receiving adjuvant platinum-based treatment (15). In
addition, the activation of Nrf2 pathway is linked to
chemoresistance in various other carcinomas (16).
Accumulating data suggest that nuclear Nrf2 expression
associates with a poor survival also in osteosarcoma,
glioblastoma, pancreatic adenocarcinoma, oral squamocellular
cancer and gastric cancer (17-21). In our study a strong Nrf2
expression in melanocytic cells was a powerful negative
prognostic factor in primary melanomas. In line with this,
nuclear Nrf2 expression in melanocytic cells associated with
deeper invasion and a nodular histology. The results reflect
Nrf2 cancer promoter role in the transformation from a radial
to a vertical growth phase.
Activating mutations of HRAS, KRAS, BRAF and cMYC
may increase the activity of Nrf2 (5, 22), attenuate lower
intracellular ROS and confer a more reduced redox state (23).
Supporting this notion, we observed that BRAF-inhibitor
vemurafenib decreased the expression of Nrf2 in BRAF-
mutated cells albeit the decrease was only minor in one of the
studied cell lines (COLO-800), suggesting possible other
Nrf2 activating processes, for instance epigenetic mechanisms
for up-regulation (14). In addition, MEK-inhibitor CI-1040
had a similar effect on NRAS-mutated cell lines. One of our
pre-study hypotheses was that the decrease in Nrf2 level
would sensitize melanoma cells to toxic effects of powerful
oxidant, H2O2. However, the combination of BRAF/NRAS-
inhibitor and H2O2 did not have a synergistic effect. COLO-
800 cell line showed even increased resistance to vemurafenib
in oxidative environment, possibly due to induced
compensatory mechanisms such as H2O2-induced signaling.
Many chemotherapeutic agents, such as dacarbazine, that is
widely used in melanomas, mediate their effect by increasing
oxidative stress damage (24). Our study suggests that it is
unlikely that in oncogene driven melanomas
chemotherapeutic agent would produce extra benefit to
appropriate oncogene inhibition. 
Keap1 did not associate with prognosis but its expression
was attenuated in malignant samples compared to benign
nevi. In malignant melanoma a stronger Keap1 intensity in
surrounding cells likewise associated with more superficial
growth. These results are in line with the inhibiting role of
Keap1 against Nrf2, since corresponding results of increasing
Keap1 expression and a less aggressive behavior of cancer
have been reported at least in pancreatic cancer (25) and
squamous non-small cell lung carcinoma (15).
8-OHdG and nitrotyrosine are the most applied markers of
oxidative stress. By immunohistochemistry 8-OHdG has been
connected to poor survival in melanoma (26), colorectal
cancer (27), diffuse large B-cell lymphoma (28) and ovarian
carcinoma (29). Our result of negative to weak 8-OHdG
intensity and poor prognosis is contradictory to a previous
report (26). This study differed from ours by a smaller sample
size, type of antibody, specific location of staining and it
consisted also of metastatic melanomas. Our observation of
worse prognosis in multivariate analysis in patients with lower
endothelial 8-OHdG expression has been observed in
pancreatic adenocarcinomas (25) and in breast cancer (30-32).
8-OHdG was significantly less expressed in malignant
melanomas compared to benign nevi and cytoplasmic 8-
OHdG expression in pigment cells also associated highly
significantly with smaller Breslow’s thickness. 
8-OHdG expression depends on DNA repair enzymes,
especially from the function of human 8-oxoguanine
glycosylase (hOGG1). Its increased activity may decrease 8-
OHdG levels. Recent evidence suggests that 8-OHdG also
acts as an antioxidant in a stress-induced gastritis model (2).
Intriguingly, 8-OHdG also prevents UVB-induced ROS-
associated skin damage in hairless mice, acting as an
antioxidant and activating MAPKs, ATF-2, and c-Jun, which
may explain its protective effect on survival in our clinical
material (33). In contrast, another oxidative stress marker,
nitrotyrosine, associated with more aggressive tumor features
and poor survival when present in apocrine cells. We did not
find any significant changes in the nitrotyrosine expression
in pigment cells.
One of the strengths of the current study was a careful
assessment of the tumor microenvironment. We separately
examined immunohistochemical results in the whole sample as
the stroma may significantly vary in relation to the supply of
oxygen in the skin (34). The current results demonstrated that
there is a great variability in oxidative stress status in stromal
cells. Hypothetically, the loss of 8-OHdG expression in
adjacent keratinocyte and fibroblast population could be a
reflection from the neoplastic process in the microenvironment.
The prognostic relevance of 8-OHdG was, however, observed
when assessing endothelial cells that are best oxygenated. 
Our results suggest, that Nrf2 could offer melanoma cells
a growth advantage with its persistent function and
attenuated elimination. With the help of Nrf2 induced
ANTICANCER RESEARCH 36: 1497-1506 (2016)
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antioxidants, melanoma can survive with hostile oxidative
stress. That being so, Nrf2 targeted therapies could offer a
strategy to improve oncological treatments, but first the
mechanisms behind Nrf2 upregulation should be carefully
investigated.
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